Alzheimer's disease

UCB's tau drug flunks phase 2 Alzheimer's trial days after Roche's exit from $120M bet
Fierce Biotech
Fri, 11/1/24 - 10:55 am
UCB Pharma
clinical trials
Roche
Alzheimer's disease
bepranemab
Roche’s Alzheimer’s test shows high negative predictive value
Clinical Trials Arena
Thu, 10/31/24 - 09:15 am
Roche
diagnostics
Alzheimer's disease
Elecsys
Roche sees rapid amyloid clearing in Alzheimer's study, adjusts protocol after patient death
Fierce Biotech
Wed, 10/30/24 - 08:47 pm
Roche
Alzheimer's disease
clinical trials
trontinemab
AbbVie doubles down on Alzheimer’s with $1.4B Aliada buy
BioSpace
Mon, 10/28/24 - 11:41 am
AbbVie
M&A
Alzheimer's disease
Aliada Therapeutics
Lilly's Alzheimer's drug gets UK nod, but no NHS funding
Pharmaphorum
Wed, 10/23/24 - 11:26 am
Eli Lilly
Alzheimer's disease
Kisunla
UK
NHS
NICE
Roche tosses out tau prospect, returning rights to UCB 4 years after placing $120M bet
Fierce Biotech
Tue, 10/22/24 - 11:25 am
Roche
UCB Pharma
anti-tau antibodies
bepranemab
Alzheimer's disease
As new Alzheimer’s biomarkers come into play, here’s where the money is going
Pharma Voice
Thu, 10/17/24 - 09:20 am
R&D
funding
Alzheimer's disease
Leqembi's vial design could result in hundreds of millions in annual Medicare waste: study
Fierce Pharma
Mon, 10/14/24 - 11:13 pm
Eisai
Biogen
Leqembi
Alzheimer's disease
Sage continues downslide as Alzheimer’s study fails
BioPharma Dive
Tue, 10/8/24 - 10:00 pm
SAGE Therapeutics
Alzheimer's disease
clinical trials
SAGE-718
Sage scraps Alzheimer's program as dalzanemdor goes 0 for 2, leaving hopes resting on Huntington's
Fierce Biotech
Tue, 10/8/24 - 09:53 am
SAGE Therapeutics
Alzheimer's disease
dalzanemdor
clinical trials
An Alzheimer’s drugmaker is accused of data ‘manipulation.’ Should its trials be stopped?
Pharma Voice
Fri, 10/4/24 - 09:19 am
Cassava Sciences
Alzheimer's disease
data manipulation
Cassava, former execs ink SEC deal to resolve allegations around misleading Alzheimer's data drop
Fierce Biotech
Mon, 09/30/24 - 09:23 am
Cassava Sciences
Alzheimer's disease
SEC
Eli Lilly's Alzheimer's drug approved in Japan
Reuters
Tue, 09/24/24 - 11:39 am
Eli Lilly
Japan
donanemab
Alzheimer's disease
Their Alzheimer’s treatment worked — but shares fell anyway
Pharma Voice
Thu, 08/29/24 - 11:06 am
Cognition Therapeutics
clinical trials
Alzheimer's disease
CT1812
Mixed reactions among HCPs as lecanemab and donanemab secure FDA approval for Alzheimer's treatment
Pharmaphorum
Mon, 08/26/24 - 10:14 am
Alzheimer's disease
physicians
Eli Lilly
Kisunla
donanemab
lecanemab
Eisai, Biogen's Leqembi nabs UK nod, but reimbursement remains elusive
Fierce Pharma
Thu, 08/22/24 - 11:45 am
Eisai
Biogen
Leqembi
UK
Alzheimer's disease
Australian biotech's cortisol blocker fails to improve attention in phase 2 depression study
Fierce Biotech
Mon, 08/12/24 - 11:31 am
Actinogen
cortisol blockers
depression
Alzheimer's disease
clinical trials
Lilly's tau drug for Alzheimer's flunks phase 2 test
Pharmaphorum
Fri, 08/9/24 - 11:18 am
Eli Lilly
Alzheimer's disease
clinical trials
LY3372689
Vaccinex’s Phase Ib/II trial for Alzheimer’s treatment hits primary endpoint
Clinical Trials Arena
Wed, 07/31/24 - 11:14 pm
Vaccinex
clinical trials
Alzheimer's disease
pepinemabin
After EU setback, Eisai/Biogen build case for Leqembi
Pharmaphorum
Wed, 07/31/24 - 10:25 am
Eisai
Biogen
Alzheimer's disease
Leqembi
Europe

Pages